Procalcitonin
Also known as: BRAHMS PCT, calcitonin precursor, PCT, Pro-calcitonin, Procalcitonin assay
Source Procalcitonin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Procalcitonin (PCT) is a blood biomarker, the precursor of the hormone calcitonin, that rises markedly during systemic bacterial infections and sepsis. Clinicians use quantitative PCT assays to help diagnose infection, differentiate bacterial from viral causes, and to guide the initiation or discontinuation of antibiotics, particularly in acute respiratory infections and intensive‑care sepsis management.
Mechanism of Action
In response to bacterial toxins and pro‑inflammatory cytokines (e.g., IL‑6, TNF‑α), many tissues up‑regulate the CALC‑1 gene, releasing the prohormone procalcitonin into circulation. Unlike calcitonin, which is involved in calcium homeostasis, PCT does not undergo cleavage to an active hormone in this setting; its serum concentration therefore reflects the magnitude of the host's systemic bacterial inflammatory response and is measured by immunoassay.
What the Research Shows
Systematic reviews and meta‑analyses show that serum PCT has moderate diagnostic accuracy for sepsis (AUC 0.85, sensitivity 0.80, specificity 0.77) and outperforms C‑reactive protein. In adult intensive‑care sepsis, PCT‑guided antibiotic discontinuation shortens therapy by about 1.9 days and reduces 30‑day mortality (≈27 fewer deaths per 1,000 patients) without increasing recurrence. Patient‑level meta‑analysis of acute respiratory infections confirms a mortality benefit (adjusted OR 0.83), a 2.4‑day reduction in antibiotic exposure, and fewer antibiotic‑related side‑effects. In children with infection, elevated PCT is consistently associated with higher mortality, supporting its inclusion in severity assessments, though interventional trials are lacking. For community‑acquired pneumonia, PCT’s sensitivity (0.55) and specificity (0.76) are insufficient to reliably rule in or out bacterial disease on their own.
Reported Benefits
Evidence indicates that using PCT to guide antibiotic decisions can shorten treatment duration, lower overall antibiotic exposure, and reduce side‑effects. In sepsis and acute respiratory infections, PCT‑guided protocols have been linked to modest but statistically significant reductions in 30‑day mortality. The biomarker also provides better diagnostic discrimination for bacterial sepsis than CRP, aiding clinicians in early identification of serious infection.
Limitations of the Evidence
The diagnostic performance of PCT varies by clinical context; its modest sensitivity for bacterial pneumonia limits its ability to replace microbiologic testing. Benefits depend on specific protocols (e.g., cutoff values, monitoring frequency), and certainty of evidence ranges from low to moderate. Pediatric data are largely observational, showing association rather than causation. Heterogeneity across studies and low‑certainty evidence for recurrence risk mean that results should be interpreted cautiously.
Safety Considerations
Procalcitonin testing involves a standard blood draw, which carries minimal risk. False‑positive elevations (e.g., after major surgery, trauma, or certain non‑infectious inflammatory states) could lead to unnecessary antibiotic use, while false‑negatives might delay needed therapy. Clinicians should interpret results in the context of clinical findings and other laboratory data to avoid mismanagement.
How It Is Administered
Procalcitonin is measured from serum or plasma obtained via peripheral venipuncture. Commercial immunoassays provide quantitative results, typically reported in µg/L. Serial measurements are common, with recommended intervals ranging from daily to every 48 hours depending on the clinical protocol. No therapeutic formulation exists; the test is used solely for diagnostic and decision‑support purposes.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
- Monitoring treatment response in sepsisPrognostic / MonitoringHigh
- Diagnosis of bacterial sepsisDiagnostic / BiomarkerHigh
- Risk stratification in lower respiratory tract infectionDiagnostic / BiomarkerHigh
- Prognosis in critically ill patientsPrognosticModerate
- Sepsis diagnosisDiagnosticHigh
- Antibiotic stewardship guidanceTherapeutic Decision SupportHigh
- Differentiation of bacterial vs. viral infectionDiagnostic / BiomarkerHigh
Contraindications
- Sole reliance for antibiotic decisions in immunocompromised patientsClinical LimitationHigh
- Use as sole diagnostic in fungal or parasitic infectionsDiagnostic LimitationModerate
Adverse Effects
- Phlebotomy-related discomfortProceduralCommon
Drug Interactions
No drug interactions recorded yet.
Population Constraints
- Patients with medullary thyroid carcinomaDisease StateRelative
- Severe renal failure (ESRD)Organ ImpairmentRelative
- Neonates (<72 hours of life)AgeRelative
- Post-major surgery or trauma patientsClinical ConditionRelative
- NeonatesPediatricRelative
Regulatory Status
- European UnionUnapprovedAvailable as in‑vitro diagnostic reagent.
- United StatesUnapprovedUsed in FDA‑cleared diagnostic kits, not as a drug.
- United KingdomApprovedApproved: Sepsis risk stratification, Antibiotic decision support in respiratory tract infectionsNICE recommends PCT testing in certain sepsis and antibiotic stewardship contexts; UKCA/CE-marked diagnostic assays available.
Not approved as a therapeutic; used in in‑vitro diagnostic assays under FDA clearance (e.g., BRAHMS PCT assay).
Evidence & Sources
- Journal ArticleHighKubo K, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleHighTan M, et al.2019-01-01T00:00:00.000000Z
- Journal ArticleHighMenon K, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleHighKamat IS, et al.2020-01-01T00:00:00.000000Z
- Journal ArticleHighSchuetz P, et al.2018-01-01T00:00:00.000000Z
- Journal ArticleHighWacker C, et al.2013-01-01T00:00:00.000000Z
Frequently Asked Questions
What clinical situations is procalcitonin most useful for?
PCT is primarily used in intensive‑care or emergency settings to help diagnose sepsis, to guide the timing of antibiotic discontinuation in sepsis and acute respiratory infections, and as part of severity assessments in pediatric infection.
Can procalcitonin replace blood cultures or imaging for diagnosing infection?
No. While PCT adds information about bacterial inflammation, it does not identify the pathogen. Blood cultures, imaging, and clinical assessment remain essential for definitive diagnosis.
Is procalcitonin reliable for distinguishing viral from bacterial pneumonia?
Meta‑analysis shows limited sensitivity (≈55 %) and moderate specificity (≈76 %). Therefore, PCT alone cannot reliably dictate whether antibiotics should be started or withheld in community‑acquired pneumonia.
What are the recommended PCT thresholds for stopping antibiotics?
Studies reporting benefit often used a cutoff of 0.5 µg/L combined with an 80 % reduction from the peak level, but exact thresholds vary by protocol and patient population.
Are there any risks associated with using procalcitonin‑guided therapy?
The test itself is low‑risk, but misinterpretation can lead to overtreatment (if non‑infectious inflammation raises PCT) or undertreatment (if bacterial infection occurs with low PCT). Clinicians should use PCT alongside clinical judgment.
What is Procalcitonin?
Procalcitonin (PCT) is a blood biomarker, the precursor of the hormone calcitonin, that rises markedly during systemic bacterial infections and sepsis. Clinicians use quantitative PCT assays to help diagnose infection, differentiate bacterial from viral causes, and to guide the initiation or discontinuation of antibiotics, particularly in acute respiratory infections and intensive‑care sepsis management.
What is Procalcitonin used for?
Procalcitonin is educationally associated with: Monitoring treatment response in sepsis, Diagnosis of bacterial sepsis, Risk stratification in lower respiratory tract infection, Prognosis in critically ill patients, Sepsis diagnosis, Antibiotic stewardship guidance, Differentiation of bacterial vs. viral infection. Educational only — not medical advice.
What are the potential side effects of Procalcitonin?
Reported adverse effects include: Phlebotomy-related discomfort. This list is not exhaustive — consult a qualified clinician.
Who should avoid Procalcitonin?
Recorded contraindications: Sole reliance for antibiotic decisions in immunocompromised patients, Use as sole diagnostic in fungal or parasitic infections. Consult a qualified clinician before use.